Get Premium to unlock powerful stock data
XSWX:COPN (Ireland)  
Cosmo Pharmaceuticals NV logo

Cosmo Pharmaceuticals NV

CHF 47.55 (+3.37%) Jun 27
P/E:
36.21
P/B:
1.51
Market Cap:
CHF 794.44M ($ 828.23M)
Enterprise V:
CHF 741.54M ($ 773.08M)
Volume:
25.09K
Avg Vol (2M):
15.37K
Also Trade In:
Volume:
25.09K
Market Cap CHF:
794.44M
Market Cap $:
828.23M
PE Ratio:
36.21
Avg Vol (2-Month):
15.37K
Enterprise Value CHF:
741.54M
Enterprise Value $:
773.08M
PB Ratio:
1.51
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download Tutorials

Business Description

Cosmo Pharmaceuticals NV
NAICS : 325412 SIC : 2834
Sir John Rogerson’s Quay, Riverside II, Dublin, IRL, 2
Description
Cosmo Pharmaceuticals NV is a major drug manufacturing company with a focus on specialty pharmaceuticals. Its clinical development pipeline maintains a focus on treatments for inflammatory bowel disease, colorectal cancer diagnosis, and colonoscopy. The company's business model involves identifying market opportunities, creating a corresponding product, advancing through the clinical trials, and then partnering its product into a specialty pharma company with strong marketing and sales expertise by taking an equity stake in the partner. While the equity stake can later be divested, Cosmo retains exclusive manufacturing of all the products it develops.
Name Current Vs Industry Vs History
Cash-To-Debt 1.31
Equity-to-Asset 0.63
Debt-to-Equity 0.34
Debt-to-EBITDA 4.19
Interest Coverage 1.2
Piotroski F-Score 6/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.62
Distress
Grey
Safe
Beneish M-Score -2.3
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
3-Year Revenue Growth Rate -6.7
3-Year Book Growth Rate -2.3
Name Current Vs Industry Vs History
5-Day RSI 73.04
9-Day RSI 56.15
14-Day RSI 48.79
6-1 Month Momentum % -20.57
12-1 Month Momentum % -39.84

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 12.99
Quick Ratio 12.37
Cash Ratio 10.46
Days Inventory 226.36
Days Sales Outstanding 105.08
Days Payable 236.23

Dividend & Buy Back

Name Current Vs Industry Vs History
Dividend Yield % 2.13
Forward Dividend Yield % 2.13
5-Year Yield-on-Cost % 2.13
3-Year Average Share Buyback Ratio -4

Financials

XSWX:COPN's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil CHF) 69.229
EPS (TTM) (CHF) 1.313
Beta 1.18
Volatility % 20.49
14-Day RSI 48.79
14-Day ATR (CHF) 1.758342
20-Day SMA (CHF) 47.2475
12-1 Month Momentum % -39.84
52-Week Range (CHF) 42.3 - 89.8
Shares Outstanding (Mil) 16.71

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 6
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Cosmo Pharmaceuticals NV Filings

Document Form Filing Date
No Filing Data